Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas.
immunotherapy
macrophage
meningiomas
tumor immunology
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
02 11 2021
02 11 2021
Historique:
pubmed:
30
4
2021
medline:
6
11
2021
entrez:
29
4
2021
Statut:
ppublish
Résumé
Malignant meningiomas are fatal and lack effective therapy. As M2 macrophages are the most prevalent immune cell type in human meningiomas, we hypothesized that normalizing this immunosuppressive population would be an effective treatment strategy. We used CIBERSORTx to examine the proportions of 22 immune subsets in human meningiomas. We targeted the colony-stimulating factor 1 (CSF1) or CSF1 receptor (CSF1R) axis, an important regulator of macrophage phenotype, using monoclonal antibodies (mAbs) in a novel immunocompetent murine model (MGS1) for malignant meningioma. RNA sequencing (RNA-seq) was performed to identify changes in gene expression in the tumor microenvironment (TME). Mass cytometry was used to delineate changes in immune subsets after treatment. We measured patients' plasma CSF1 levels using ELISA and CSF1R expression using multiplex quantitative immunofluorescence in a human meningioma tissue microarray. Human meningiomas are heavily enriched for immunosuppressive myeloid cells. MGS1 recapitulates the TME of human meningiomas, including an abundance of myeloid cells, a paucity of infiltrating T cells, and low programmed death ligand 1 (PD-L1) expression. Treatment of murine meningiomas with anti-CSF1/CSF1R, but not programmed cell death receptor 1 (PD-1), mAbs abrogate tumor growth. RNA-seq and mass cytometry analyses reveal a myeloid cell reprogramming with limited effect on T cells in the TME. CSF1 plasma levels are significantly elevated in human patients, and CSF1R is highly expressed on CD163+ macrophages within the human TME. Our findings suggest that anti-CSF1/CSF1R antibody treatment may be an effective normalization cancer immunotherapy for malignant meningiomas.
Sections du résumé
BACKGROUND
Malignant meningiomas are fatal and lack effective therapy. As M2 macrophages are the most prevalent immune cell type in human meningiomas, we hypothesized that normalizing this immunosuppressive population would be an effective treatment strategy.
METHODS
We used CIBERSORTx to examine the proportions of 22 immune subsets in human meningiomas. We targeted the colony-stimulating factor 1 (CSF1) or CSF1 receptor (CSF1R) axis, an important regulator of macrophage phenotype, using monoclonal antibodies (mAbs) in a novel immunocompetent murine model (MGS1) for malignant meningioma. RNA sequencing (RNA-seq) was performed to identify changes in gene expression in the tumor microenvironment (TME). Mass cytometry was used to delineate changes in immune subsets after treatment. We measured patients' plasma CSF1 levels using ELISA and CSF1R expression using multiplex quantitative immunofluorescence in a human meningioma tissue microarray.
RESULTS
Human meningiomas are heavily enriched for immunosuppressive myeloid cells. MGS1 recapitulates the TME of human meningiomas, including an abundance of myeloid cells, a paucity of infiltrating T cells, and low programmed death ligand 1 (PD-L1) expression. Treatment of murine meningiomas with anti-CSF1/CSF1R, but not programmed cell death receptor 1 (PD-1), mAbs abrogate tumor growth. RNA-seq and mass cytometry analyses reveal a myeloid cell reprogramming with limited effect on T cells in the TME. CSF1 plasma levels are significantly elevated in human patients, and CSF1R is highly expressed on CD163+ macrophages within the human TME.
CONCLUSION
Our findings suggest that anti-CSF1/CSF1R antibody treatment may be an effective normalization cancer immunotherapy for malignant meningiomas.
Identifiants
pubmed: 33914067
pii: 6259024
doi: 10.1093/neuonc/noab075
pmc: PMC8563319
doi:
Substances chimiques
CSF1 protein, human
0
CSF1R protein, human
0
Receptors, Granulocyte-Macrophage Colony-Stimulating Factor
0
Macrophage Colony-Stimulating Factor
81627-83-0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1922-1935Subventions
Organisme : NCATS NIH HHS
ID : KL2 TR001862
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA046934
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001863
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
Oncotarget. 2015 Oct 20;6(32):32713-22
pubmed: 26418719
Front Immunol. 2019 Feb 01;9:3101
pubmed: 30774636
Cancer Res. 2010 Jul 15;70(14):5728-39
pubmed: 20570887
Cell. 2018 Oct 4;175(2):313-326
pubmed: 30290139
Front Pharmacol. 2018 May 22;9:536
pubmed: 29910728
JCO Precis Oncol. 2018;2018:
pubmed: 30801050
J Clin Invest. 2002 Mar;109(5):651-9
pubmed: 11877473
Neurosurg Focus. 2018 Apr;44(4):E3
pubmed: 29606052
J Neurooncol. 2016 Dec;130(3):543-552
pubmed: 27624915
Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1692-1697
pubmed: 30635425
Cancer Res. 2014 Sep 15;74(18):5057-69
pubmed: 25082815
Oncotarget. 2015 Mar 10;6(7):4704-16
pubmed: 25609200
J Neuropathol Exp Neurol. 2021 Jan 20;80(2):150-159
pubmed: 33393633
Oncogene. 2013 Sep 5;32(36):4264-72
pubmed: 23045274
Int J Cancer. 2010 Mar 15;126(6):1339-52
pubmed: 19711348
J Clin Neurosci. 2018 Nov;57:149-151
pubmed: 30153998
Blood. 2012 Feb 23;119(8):1810-20
pubmed: 22186992
J Immunother Cancer. 2017 Jul 18;5(1):53
pubmed: 28716061
Nat Methods. 2015 May;12(5):453-7
pubmed: 25822800
Science. 2013 Mar 1;339(6123):1077-80
pubmed: 23348505
J Neurooncol. 2018 Sep;139(2):469-478
pubmed: 29846894
Nat Commun. 2017 Feb 14;8:14433
pubmed: 28195122
Cancer. 1999 May 1;85(9):2046-56
pubmed: 10223247
Nature. 2016 Nov 17;539(7629):437-442
pubmed: 27642729
Sci Rep. 2019 Feb 28;9(1):3172
pubmed: 30816272
Oncoimmunology. 2013 Dec 1;2(12):e26968
pubmed: 24498562
Cell. 2015 Jul 2;162(1):184-97
pubmed: 26095251
Trends Immunol. 2002 Nov;23(11):549-55
pubmed: 12401408
J Neurooncol. 2010 Sep;99(3):307-14
pubmed: 20821343
Cancer Cell. 2017 Nov 13;32(5):654-668.e5
pubmed: 29136508
JAMA Oncol. 2016 Nov 1;2(11):1403-1404
pubmed: 27490017
Proc Natl Acad Sci U S A. 1990 Aug;87(15):5613-7
pubmed: 2165597
Blood. 2007 Jul 1;110(1):180-5
pubmed: 17289811
Trends Cell Biol. 2004 Nov;14(11):628-38
pubmed: 15519852
JCI Insight. 2018 Jun 7;3(11):
pubmed: 29875321
Neuro Oncol. 2013 Nov;15(11):1479-90
pubmed: 23978377
Cell. 2017 Nov 16;171(5):1042-1056.e10
pubmed: 29056344
Nat Med. 2007 Jan;13(1):84-8
pubmed: 17159987
Cancer Res. 2005 Feb 1;65(3):1089-96
pubmed: 15705911
Neurooncol Adv. 2019 Sep 19;1(1):vdz018
pubmed: 32642654
Sci Transl Med. 2018 Apr 11;10(436):
pubmed: 29643229
Sci Rep. 2018 Jan 10;8(1):256
pubmed: 29321503
Nat Med. 2002 Nov;8(11):1323-7
pubmed: 12389040
Cancer Cell. 2014 Jun 16;25(6):846-59
pubmed: 24898549
J Thorac Oncol. 2018 Dec;13(12):1884-1896
pubmed: 30267840
Clin Cancer Res. 2012 Oct 1;18(19):5212-23
pubmed: 22837179
Nat Genet. 2016 Oct;48(10):1253-9
pubmed: 27548314
PLoS Comput Biol. 2016 Sep 23;12(9):e1005112
pubmed: 27662185